Delta-Fly Pharma, Inc. (4598.T) Comparison with companies in other sectors?

Delta-Fly Pharma, Inc. has a share price of 11.52M. You can analyze Delta-Fly Pharma, Inc. (4598.T) competitors across different market sectors through stock heatmaps.

What are 4598.T's NET and operating margins?

Delta-Fly Pharma, Inc. (4598.T) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does 4598.T's earnings per share (EPS) trend reflect its financial momentum?

Delta-Fly Pharma, Inc. (4598.T) EPS is -195.60 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Delta-Fly Pharma, Inc. is -3.56, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Delta-Fly Pharma, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Delta-Fly Pharma, Inc. like P/E which is -3.66, P/B which is 22.65, and PEG which is -0.55. Compare them with sector averages to evaluate if the stock is priced fairly.

Delta-Fly Pharma, Inc.

4598.T•JPX

Healthcare

Biotechnology

¥697.00

¥-14.00(-1.97%)

Delta-Fly Pharma, Inc. (4598.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-195.60

P/E Ratio

-3.56

ROE

-3.42%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.03B

Shares OutstandingTotal number of shares issued

$11.52M

Book Value/ShareNet worth per share

$30.77

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-195.6

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-341.89%

ROAReturn on total assets

-396.10%

ROCEReturn on capital employed

-614.65%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$37.53

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 4598.TFinancial Ratios Analysis details for 4598.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 4598.TSector Benchmarking details for 4598.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Delta-Fly Pharma, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Delta-Fly Pharma, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Delta-Fly Pharma, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Delta-Fly Pharma, Inc.

For Delta-Fly Pharma, Inc., essential financial indicators include EPS -195.60, PE -3.56, and ROE -3.42. These key ratios reveal insights into Delta-Fly Pharma, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Delta-Fly Pharma, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Delta-Fly Pharma, Inc.

Metrics like Net Margin - and ROA -396.10% shed light on how well Delta-Fly Pharma, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Delta-Fly Pharma, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Delta-Fly Pharma, Inc.

Using ratios such as P/B Ratio 22.65 and PEG Ratio -0.55, investors can assess whether Delta-Fly Pharma, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Delta-Fly Pharma, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Delta-Fly Pharma, Inc.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow -, provide a snapshot of Delta-Fly Pharma, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Delta-Fly Pharma, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Delta-Fly Pharma, Inc.

Investing in Delta-Fly Pharma, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Delta-Fly Pharma, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;